Results 31 to 40 of about 32,386 (229)

Sex Differences in Medication Discontinuation in Axial Spondyloarthritis

Arthritis Care &Research, EarlyView.
Objective We examined sex differences in medication discontinuation among patients with axial spondyloarthritis (axSpA) initiating tumor necrosis factor inhibitors (TNFi), interleukin‐17 inhibitors (IL‐17i), or JAK inhibitors (JAKi). Methods Using data from the Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), we assessed ...
Rachael Stovall, Cinthia Blat, Eric Roberts, Jean W. Liew, Katherine Wysham, Namrata Singh, Janna Friedly, Lianne S. Gensler, Gabriela Schmajuk, Jinoos Yazdany   +9 more
wiley   +1 more source

Adalimumab

Annales de Dermatologie et de Vénéréologie, 2019
  +10 more sources

Smart, Bio‐Inspired Polymers and Bio‐Based Molecules Modified by Zwitterionic Motifs to Design Next‐Generation Materials for Medical Applications

Advanced Functional Materials, EarlyView.
Bio‐based and (semi‐)synthetic zwitterion‐modified novel materials and fully synthetic next‐generation alternatives show the importance of material design for different biomedical applications. The zwitterionic character affects the physiochemical behavior of the material and deepens the understanding of chemical interaction mechanisms within the ...
Theresa M. Lutz, Jonas De Breuck, Sahar Salehi, Meike N. Leiske   +3 more
wiley   +1 more source

Increased Anti‐Psoriatic Effect of Anti‐Inflammatory Dendrimers Using Fluid Catanionic Vesicle‐Based Topical Formulations

Advanced Healthcare Materials, EarlyView.
Next‐Generation Psoriasis Therapy – With advanced dendrimer‐based formulations, this study paves the way for highly effective, skin‐permeable treatments. Encapsulated in fluid catanionic vesicles, IMD‐006 and its analogues show promising anti‐psoriatic effects offering a targeted, non‐invasive approach to managing chronic skin inflammation.
Ranime Jebbawi, Abdelouahd Oukhrib, Emily Clement, Hélène Labie, Stéphanie Cassel, Séverine Fruchon, Anne‐Marie Caminade, Michel Simon, Rémy Poupot, Cédric‐Olivier Turrin, Muriel Blanzat   +10 more
wiley   +1 more source

Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases

Pediatric Rheumatology Online Journal
Background In pediatric rheumatic diseases (PRD), adalimumab is dosed using fixed weight-based bands irrespective of methotrexate co-treatment, disease activity (DA) or other factors that might influence adalimumab pharmacokinetics (PK).
Tatjana Welzel, Klervi Golhen, Andrew Atkinson, Verena Gotta, David Ternant, Jasmin B. Kuemmerle-Deschner, Christine Michler, Gilbert Koch, Johannes N. van den Anker, Marc Pfister, Andreas Woerner   +10 more
doaj   +1 more source

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

Arthritis Research & Therapy, 2021
Background To demonstrate equivalent efficacy of the proposed high-concentration (100 mg/ml), citrate-free adalimumab biosimilar CT-P17 to European Union-approved adalimumab (EU-adalimumab) in subjects with active rheumatoid arthritis (RA).
Jonathan Kay, Janusz Jaworski, Rafal Wojciechowski, Piotr Wiland, Anna Dudek, Marek Krogulec, Slawomir Jeka, Agnieszka Zielinska, Jakub Trefler, Katarzyna Bartnicka-Maslowska, Magdalena Krajewska-Wlodarczyk, Piotr A. Klimiuk, Sang Joon Lee, Yun Ju Bae, Go Eun Yang, Jae Kyoung Yoo, Daniel E. Furst, Edward Keystone   +17 more
doaj   +1 more source

Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges

Advanced Healthcare Materials, EarlyView.
This review explores the evolving role of microneedle systems in psoriasis management, highlighting their potential for enhanced drug delivery, diagnosis, and disease monitoring. It also discusses unmet clinical needs for psoriasis management and technical challenges, while outlining strategic directions to advance microneedle integration into routine ...
Fatma Moawad, Yasmine Ruel, Roxane Pouliot, Davide Brambilla   +3 more
wiley   +1 more source

Multiomics Analyses Reveal an Essential Role of Tryptophan in Treatment of csDMARDs in Rheumatoid Arthritis

Advanced Science, EarlyView.
Rheumatoid arthritis is a disease characterized by joint inflammation. Approximately 50% of patients show insufficient response to traditional synthetic disease‐modifying antirheumatic drugs. This study aims to elucidate differential molecular profiles of the mechanisms underlying drug responses through multi‐omics strategy.
Congcong Jian, Jing Zhu, Jianhong Wu, Yan Zhang, Jianghua Chen, Huan Wang, Hengyan Liu, Ke Xu, Jiaxin Huang, Xiaoting Zhu, Yuanli Wei, Shilin Li, Tingting Wang, Xuan Huang, Qinghua Zou, Jie Zhang, Jiang Su, Xinming Du, Yaping Lu, Tianci Zhou, Yingtong Zhou, Minglong Tang, Bin Li, Xue Zhou, Qihao Wei, Qiulong Yan, Fanxin Zeng   +26 more
wiley   +1 more source

Levels of antibodies to adalimumab in children with juvenile idiopathic arthritis at different stages of treatment

Zdorovʹe Rebenka, 2023
Background. Juvenile idiopathic arthritis (JIA) is one of the most common rheumatological diseases of childhood. The central place in the problem of JIA belongs to the question of treatment the timeliness and adequacy of which determine the disease ...
T.V. Marushko, O.Ye. Onufreiv, Yu.V. Marushko, O.B. German   +3 more
doaj   +1 more source

Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis

Arthritis &Rheumatology, EarlyView.
Rheumatoid arthritis (RA) is a complex systemic disorder characterized primarily by articular inflammation and destruction with associated functional loss and reduced quality of life. RA is also associated with extra‐articular disease, such as that of the lung, with potentially devastating clinical consequences. The critical importance of comorbidities,
Aurelie Najm, Lyn D. Ferguson, Iain B. McInnes   +2 more
wiley   +1 more source